Business
DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce a collaboration with AlyaTec, a globally renowned Contract Research Organization (CRO), specializing in allergy and environmental diseases, to initiate a clinical study of TeaRx™ Red Eye in order to advance the global commercialization of TeaRx™ Red Eye and...
About this update from Diagnostear Technologies, Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce a collaboration with AlyaTec, a globally renowned Contract Research Organization (CRO), specializing in allergy and environmental diseases, to initiate a clinical study of TeaRx™ Red Eye in order to advance the global commercialization of TeaRx™ Red Eye and strengthen its FDA submission pathway.","length":554,"tagName":"p"},{"type":"text","content":"TeaRx™ Red Eye is being developed as the first rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis at the point of care. These three conditions drive hundreds of millions of clinic visits every year, yet misdiagnosis remains widespread due to the absence of fast, accurate testing. TeaRx™ aims to change that with a simple test that delivers clinical answers in minutes.","length":466,"tagName":"p"},{"type":"text","content":"The new study with AlyaTec will examine documented allergy patients and collect tear samples before and after a controlled provocation of ocular allergy. Thirty patients are planned for enrollment, with approvals and site setup expected to take approximately 3 months, followed by 2-3 months of patient recruitment.","length":315,"tagName":"p"},{"type":"text","content":"All samples will undergo independent, quantitative testing of total tear IgE, and results will be compared to DiagnosTear's TeaRx™ Red Eye assay. This work is designed to finalize the validation, and the analytical characterization of tear IgE as a biomarker for allergic conjunctivitis and to reinforce the Company's scientific case for its comprehensive Red Eye diagnostic panel.","length":389,"tagName":"p"},{"type":"text","content":""This collaboration with AlyaTec represents a strong accelerator for our Red Eye program," said Dr. Shimon Gross, CEO of DiagnosTear. "Accurate differentiation of red eye conditions has been a long-standing unmet need. Our goal is to deliver a test that gives clinicians immediate clarity, improves patient management, and reduces unnecessary treatments. This study moves us significantly closer to that vis...